Compare Merck & Co., Inc. (MRK) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nucor Corporation — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Nucor Corporation trades at $230.8 (market cap $52.55B). The key difference: Merck & Co., Inc. is far larger — about 5.8× Nucor Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | NUE | |
|---|---|---|
Market Cap | $307.25B | $52.55B |
Sector | Health | Basic Materials |
52-Week High | $129.52 | $266.35 |
52-Week Low | $77.60 | $131.78 |
Enterprise Value | $350.66B | $57.19B |
Dividend Yield | 2.73% | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Nucor (NUE) trades at $233.2, down 1.44% over 24 hours, with technical indicators showing a bearish trend near key support at $228. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has stabilized around $32.5B in 2025 after declines from 2022 peaks, while net margins compressed to 5.36%. Analyst sentiment remains positive with a 62.5% buy rating and $263.11 consensus target, supported by strong cash flow and a 53-year dividend growth streak.
NUE offers value with reasonable valuation multiples (P/E 22.89, P/S 1.55) and robust shareholder returns, but faces risks from steel demand volatility and margin pressure. The upcoming Q2 earnings report on July 27, 2026, will be critical for confirming growth trajectory amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
